Understand the source comparison
Best Peptides for Motion Sickness: Research Application Comparison
Cerebrolysin Neurotrophic factor delivery (BDNF, NGF, CNTF) Protects vestibular neurons from oxidative stress and age-related degeneration Intramuscular or intravenous injection Refrigerate at 2–8°C; avoid temperature excursions above 25°C Best for neuroprotec
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Neurotrophic factor delivery (BDNF, NGF, CNTF)
- Protects vestibular neurons from oxidative stress and age-related degeneration
- Intramuscular or intravenous injection
- Refrigerate at 2–8°C; avoid temperature excursions above 25°C
- Best for neuroprotection in chronic vestibular dysfunction; not an acute intervention
- P21
- CREB pathway activation
- Enhances synaptic plasticity in brainstem vestibular nuclei, accelerating habituation
- Intranasal administration
- Store lyophilized powder at −20°C; reconstituted solution at 2–8°C, use within 28 days
- Strongest evidence for accelerating vestibular adaptation; requires consistent dosing over days to weeks
- Dihexa
- HGF/c-Met pathway modulation
- Promotes synaptogenesis and neural repair in vestibular pathways
- Oral or subcutaneous
- Store lyophilized powder at −20°C; oral bioavailability allows flexible dosing
- Theoretical application strong; direct vestibular research limited
- KPV
- NF-κB inhibition, anti-inflammatory
- Reduces inner ear and brainstem inflammation that amplifies vestibular mismatch
- Subcutaneous injection or intranasal
- Store lyophilized powder at −20°C; reconstituted solution at 2–8°C
- Most relevant when vestibular symptoms are inflammation-driven; less effective for pure motion mismatch
- Thymalin
- Immune modulation, systemic anti-inflammatory
- Reduces autoimmune inner ear damage and neuroinflammation in vestibular nuclei
- Subcutaneous injection
- Targeted to autoimmune vestibular conditions; not applicable to typical motion sickness